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The Editorial on the Research Topic
The Cell Types of Fibrosis
Fibrosis is a symptom that is present in multiple diseases. It is the common scarring endpoint that
is associated with the excessive generation and accumulation of collagen and other matrix proteins.
This increase in matrix causes an increase in tissue stiffness, which impacts normal tissue function
such as causing impaired gas exchange in the lung, reduced urinary filtration, and output in the
kidney, or cirrhosis and portal hypertension in the liver. This ultimately often causes a significant
impact on health, as highlighted by the “Living with Fibrosis” article by Sleeman et al. in this
Research Topic.
There are numerous mechanisms, cell types and mediators associated with the pathology.
The cell types commonly found in areas of active fibrosis are those classically associated with a
wound healing response, namely tissue fibroblasts and myofibroblasts (and shown on the front
cover). However, in normal wound healing, there are a number of “stop signals” that switch off
the reparative fibrotic response, allowing for the wound to remodel and excessive scar tissue
to be absorbed. In contrast, tissue fibrosis associated with chronic disease tends to continue
unabated. This Research Topic is focused on the cell types that have been associated with fibrosis
and highlights some of the cutting edge research from groups exploring the initiating factors,
propagating signals, and resolving pathways that may elucidate therapeutic approaches to fibrotic
diseases.
Fibrosis research is a very challenging area, as many animal models have demonstrated key
pathways that when modulated demonstrate efficacy pre-clinically, yet have disappointed in
patients. This has caused a challenge in the suitability of preclinical models, in particular in vivo
models and is justified as fibrotic diseases such as IPF or diabetic nephropathy are thought to arise
after years of repeated chronic microtrauma. Yet we are using models of acute injury to assess “key
pathways.” For example, idiopathic pulmonary fibrosis (IPF) is a disease of aging, with patients
often diagnosed later in life, yet we often assess 6–8 week old mice, days or weeks after inducing
injury. We are therefore trying to recapitulate chronic disease in an artificially confined laboratory
environment. However, we must still appreciate that these models have added a vast amount to
our understanding of chronic and complex disease environments and that we will benefit from
current research groups seeking to further improve these models. Using primary cells from patients
with fibrosis is another key aspect of pre-clinical fibrosis research. These studies have highlighted
important differences between healthy cells and fibrotic cells and are a principal pre-clinical tool.
At the disease level, Gardet et al. review the current understanding of the underlying genetic
predispositions that make individuals susceptible to fibrosis. There are common risks factors such
as environmental causes or drug treatments and even familial cases of fibrosis; however, we are
only now appreciating how certain patients may have a pre-determined susceptibility in sporadic
fibrosis. These advances in understanding may help identify approaches to prevent fibrosis. Also,
at the disease level, Mancini and Sonis review how multiple cell types are modulated during cancer
treatments, resulting in tissue fibrosis. This is often an under-appreciated area in fibrosis research;
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however, it does have a significant impact on cancer patients, both
in limiting cancer treatments, and the ensuing fibrosis causing
significant morbidity.
A great deal of fibrosis research is focused on resident
fibroblasts and myofibroblasts and their role in driving tissue
fibrosis. Habiel and Hogaboam describe the heterogeneous
nature of fibroblast in the IPF lung. In the liver, Xu et al.
also report on heterogeneity within hepatic myofibroblast
populations. Another important resident cell type, the
epithelium, is known to be altered in IPF, and Camelo et al.
review the current understanding and the role this altered
phenotype may play in disease. Mutsaers et al. describe another
key resident structural cell, the mesothelium, and how this cell
type exhibits altered phenotype and responses in fibrotic setting.
The role of inflammation in disease remains controversial,
particularly due to the lack of efficacy of immunosuppressant
therapies in most fibrotic indications. However, our ability to
profile specific inflammatory cell types is improving and thus
may open novel therapeutic approaches. One inflammatory cell
that is often found in fibrotic tissue is the mast cell, and
Overed-Sayer et al. review the controversy that has surrounded
this particular cell type in tissue fibrosis. Another cell type
described in fibrosis is the “fibrocyte,” often debated due to the
lack of consistency of cell markers and cellular compartments
between groups when defining these cells. Reese et al. profile
the fibrocyte phenotype in on-going experimental lung fibrosis,
indicating that circulating fibrocyte markers alter when the cell
type transitions into on-going tissue fibrosis.
A number of novel pathways are reported on in this Research
Topic. Agarwal’s article reviews the expression and function
of a diverse group of proteins, the integrins and cadherins.
Traditionally these proteins are thought to regulate cell–cell and
cell–matrix adhesion, yet novel functions have more recently
been described. Kendall and Feghali-Bostwick also eloquently
describe novel pathways that may also be central to pro-fibrotic
processes, including how matrix proteins regulate fibroblast and
myofibroblast function. Lee et al. present data on caveolin-1
regulating bone marrow derived pro-fibrotic cells in skin fibrosis;
Peng et al. report on the role and regulation of the fibroblast
growth factor 9 (FGF9 pathway in the experimental fibrotic lung;
and Ahsan and Mehal describe the importance of a component
of the adenosine pathway in liver fibrosis.
The articles contained in this Research Topic highlight that
there is no single cell type that drives tissue fibrosis across
the organs. The breadth of the articles also highlight the
complex nature of fibrosis and the field needs to pull together,
across the different organs affected by fibrosis, and appreciate
the similarities as well as the diversity, at the author and
reviewer level, as described by Dr. Mehal. There may also not
be a single pathway that can be modulated that will impact
fibrosis across multiple organs, even though the end stage
collagen appears very similar. Fundamentally, our understanding
on the heterogeneity of disease needs to improve. Previous
research using patient samples has often relied on tissue samples
from autopsy, highlighting terminal pathways, which may have
deteriorated in the tissue due to imprecise collection techniques.
Moreover, samples reported in the literature have often been
taken at time of diagnosis (i.e., diagnostic biopsies), which again
provides a snap shot of disease. We are only just beginning to
understand progression of disease using longitudinal samples.
However, as our understanding advances and our appreciation
of commonalities across fibrotic diseases improves, we may
more rapidly and efficiently be able to address these devastating
diseases.
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